Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration (PERSEUS)
PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea®) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration
Sponsor: Bayer
Listed as NCT01914380, this observational or N/A phase trial focuses on Wet Age-related Macular Degeneration and remains completed. Sponsored by Bayer, it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 3 earlier versions
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .